Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
2.92
Dollar change
+0.01
Percentage change
0.34
%
IndexRUT P/E- EPS (ttm)-0.47 Insider Own25.34% Shs Outstand157.46M Perf Week0.34%
Market Cap489.65M Forward P/E- EPS next Y-0.42 Insider Trans-0.08% Shs Float125.20M Perf Month24.26%
Income-75.47M PEG- EPS next Q-0.12 Inst Own46.91% Short Float4.89% Perf Quarter59.56%
Sales22.24M P/S22.02 EPS this Y5.22% Inst Trans4.89% Short Ratio6.26 Perf Half Y42.44%
Book/sh0.71 P/B4.10 EPS next Y3.67% ROA-41.64% Short Interest6.12M Perf Year5.80%
Cash/sh0.80 P/C3.65 EPS next 5Y- ROE-56.99% 52W Range1.69 - 3.14 Perf YTD16.80%
Dividend Est.- P/FCF- EPS past 5Y21.66% ROI-58.53% 52W High-7.15% Beta2.05
Dividend TTM- Quick Ratio6.34 Sales past 5Y82.54% Gross Margin93.92% 52W Low72.78% ATR (14)0.11
Dividend Ex-Date- Current Ratio6.34 EPS Y/Y TTM0.62% Oper. Margin-352.80% RSI (14)75.28 Volatility2.43% 4.57%
Employees98 Debt/Eq0.08 Sales Y/Y TTM-38.19% Profit Margin-339.32% Recom1.40 Target Price4.60
Option/ShortYes / Yes LT Debt/Eq0.08 EPS Q/Q-3.18% Payout- Rel Volume0.85 Prev Close2.91
Sales Surprise-1.94% EPS Surprise-7.14% Sales Q/Q-21.74% EarningsFeb 29 BMO Avg Volume978.62K Price2.92
SMA2010.86% SMA5018.80% SMA20032.36% Trades Volume830,927 Change0.34%
Date Action Analyst Rating Change Price Target Change
Feb-02-22Upgrade Jefferies Hold → Buy $5
Feb-25-21Initiated Jefferies Hold $5
Dec-17-20Initiated H.C. Wainwright Buy $10
Jul-27-20Resumed JMP Securities Mkt Outperform $10 → $8
Jul-24-20Downgrade Robert W. Baird Outperform → Neutral
May-19-20Upgrade Wedbush Neutral → Outperform
Mar-06-20Upgrade Chardan Capital Markets Neutral → Buy $5
Feb-20-20Initiated Robert W. Baird Outperform $8
Feb-05-20Upgrade JMP Securities Mkt Perform → Mkt Outperform $10
Oct-07-19Reiterated B. Riley FBR Buy $7 → $3
Feb-15-24 07:30AM
Jan-08-24 07:30AM
Nov-09-23 04:24PM
04:01PM
09:12AM
07:30AM Loading…
Nov-08-23 07:30AM
01:16AM
Nov-07-23 08:05AM
07:40AM
07:30AM
07:15AM
Oct-30-23 09:32AM
Oct-24-23 07:30AM
Oct-18-23 07:30AM
Oct-11-23 08:05AM
10:56AM Loading…
Sep-12-23 10:56AM
08:58AM
Sep-11-23 04:15PM
Sep-07-23 07:30AM
Aug-04-23 03:29PM
Aug-03-23 08:55AM
07:49AM
07:30AM
Jul-23-23 10:19AM
Jul-20-23 07:30AM
Jul-12-23 07:30AM
Jul-10-23 04:01PM
Jun-23-23 09:40AM
Jun-21-23 07:30AM
02:01AM
09:40AM Loading…
Jun-07-23 09:40AM
02:01AM
Jun-01-23 11:29AM
May-31-23 07:30AM
May-30-23 09:26AM
May-29-23 10:08AM
May-22-23 09:40AM
May-17-23 07:38AM
May-09-23 12:00PM
07:30AM
May-04-23 11:52PM
09:40AM
08:55AM
07:30AM
Apr-27-23 03:20AM
Apr-25-23 11:57AM
11:50AM
07:30AM
Apr-20-23 07:30AM
Apr-18-23 04:01PM
02:18PM
Apr-12-23 12:37PM
Apr-11-23 03:30PM
01:00PM
Apr-04-23 04:08PM
08:22AM
08:17AM
07:52AM
Mar-24-23 12:29PM
Mar-19-23 10:17AM
Mar-16-23 07:30AM
Mar-14-23 04:05PM
Mar-10-23 06:36PM
Mar-06-23 01:55AM
Mar-03-23 03:50AM
Mar-02-23 09:25AM
07:30AM
Feb-16-23 07:30AM
Feb-15-23 12:02PM
Feb-13-23 07:01AM
Feb-06-23 07:30AM
Jan-27-23 07:30AM
Jan-11-23 10:24PM
Jan-05-23 07:30AM
Dec-13-22 07:30AM
Dec-08-22 06:34AM
Nov-11-22 05:20AM
Nov-09-22 08:45AM
07:30AM
Nov-08-22 07:30AM
Nov-01-22 04:01PM
Oct-31-22 04:02PM
Oct-26-22 07:30AM
Oct-09-22 10:05AM
Sep-30-22 09:00AM
Sep-22-22 07:30AM
Sep-06-22 07:30AM
06:54AM
Sep-01-22 12:38PM
Aug-30-22 07:30AM
Aug-26-22 09:41AM
Aug-10-22 06:26AM
Aug-04-22 07:30PM
09:05AM
07:30AM
Jul-21-22 07:30AM
Jul-20-22 04:10PM
Jul-06-22 12:00PM
Jun-28-22 03:36PM
Jun-25-22 04:05AM
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McElhaugh Michael J.Interim President & CEOFeb 02Sale2.3110,16423,5041,504,793Feb 05 07:54 PM
Sofia Michael J.Chief Scientific OfficerFeb 02Sale2.319,98223,0831,485,121Feb 05 07:54 PM
HASTINGS DAVID CChief Financial OfficerFeb 02Sale2.319,59322,184181,907Feb 05 07:54 PM
Sims KarenChief Medical OfficerFeb 02Sale2.314,35810,078125,542Feb 05 07:55 PM